Semnur Pharmaceuticals has completed its business combination with Denali Capital Acquisition Corp., with the combined entity retaining the Semnur name and beginning OTC trading under the symbols SMNR and SMNRW on September 23, 2025. Post-transaction, Scilex and its affiliates hold approximately 87.5% of Semnur’s common stock. The company’s focus is advancing SP-102 (Semdexa), a novel epidural viscous gel formulation of dexamethasone sodium phosphate for chronic lumbosacral radicular pain (sciatica), with one Phase 3 study completed and a second pivotal program planned.
Beyond the deal mechanics, this is a strategic bid to ring-fence capital and operational focus around a single late-stage, non-opioid pain asset while leveraging a parent with commercial pain infrastructure. Listing on the OTC rather than a national exchange suggests a pragmatic route to public currency without ceding control, but it raises a critical question: can an OTC-listed, majority-controlled vehicle marshal sufficient capital and market attention to finish development, file an NDA, and execute the payer and HCP groundwork required for a procedure-embedded launch?
The timing matters. Chronic radicular pain remains a high-burden, opioid-adjacent condition with millions of U.S. patients cycling through low-cost generic epidural steroid injections, variable efficacy, and repeat procedures. SP-102 aims to differentiate through a non-particulate corticosteroid in a viscous gel intended to prolong residency and potentially deliver more durable relief, a proposition aligned with the FDA Fast Track designation granted in 2017. For patients, the promise is fewer procedures and less reliance on systemic therapies. For payers, the hurdle will be economic: any premium-priced, single-source formulation must demonstrate superiority versus entrenched generic injections on clinically meaningful endpoints and total cost of care, including avoidance of surgery, repeat injections, imaging, and disability. For HCPs—especially interventional pain physicians, anesthesiologists, and PM&R specialists—the value story must translate into guideline traction, coding clarity, and practical workflow fit in ambulatory settings.
The commercial path is as much about reimbursement architecture as clinical results. Success will hinge on securing appropriate HCPCS/J-code reimbursement, clarifying site-of-care economics, and building a robust real-world evidence plan that augments pivotal data with opioid-sparing metrics, durability beyond 12 weeks, and health economic outcomes. Medical Affairs will need to engage spine and pain societies early, address historical safety concerns around epidural steroids by emphasizing a non-particulate profile, and generate pragmatic evidence that resonates with payers skeptical of marginal reformulations. Competitively, SP-102 enters a pain market in flux, where neuromodulation, ablation, and emerging non-opioid pharmacology (including selective sodium channel blockers) are all vying to redefine standards of care. Any delay or equivocal data risks ceding mindshare to device-based alternatives that already enjoy procedural reimbursement.
This transaction also reflects broader industry dynamics. SPACs have largely cooled, but specialty carve-outs continue to use public vehicles to finance late-stage assets when traditional biotech equity remains selective. Control by a revenue-generating parent can provide commercial leverage and CMC expertise, though thin public floats may constrain liquidity and institutional sponsorship. For business development teams, Semnur’s structure could facilitate focused partnerships on ex-U.S. rights or co-promotion while preserving parent-level optionality.
The next 12 months will be decisive. Watch for the design and initiation of the second Phase 3 trial, clarity on CMC scale-up for a gel-based injectable, signals on coding strategy, and peer-reviewed publication of prior pivotal data. The strategic question for senior leaders across Commercial and Medical Affairs is straightforward: can Semnur convert a formulation-driven innovation into payer-backed clinical differentiation in a procedure-dominated market before competing non-opioid modalities reset treatment algorithms?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
